SG11202002731YA - Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one - Google Patents
Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-oneInfo
- Publication number
- SG11202002731YA SG11202002731YA SG11202002731YA SG11202002731YA SG11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA SG 11202002731Y A SG11202002731Y A SG 11202002731YA
- Authority
- SG
- Singapore
- Prior art keywords
- difluorophenethyl
- undecan
- diazaspiro
- oxa
- salts
- Prior art date
Links
- KALIKXMQWFLZKB-CQSZACIVSA-N (2R)-9-[2-(2,5-difluorophenyl)ethyl]-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one Chemical class FC1=C(CCN2CCC3(CN(C([C@H](O3)C)=O)CC)CC2)C=C(C=C1)F KALIKXMQWFLZKB-CQSZACIVSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17382695 | 2017-10-17 | ||
PCT/EP2018/000470 WO2019076475A1 (en) | 2017-10-17 | 2018-10-16 | (R) -9- (2,5-DIFLUOROPHENETHYL) -4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO SALTS [5.5] UNDECAN-3-ONE |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002731YA true SG11202002731YA (en) | 2020-05-28 |
Family
ID=60201976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002731YA SG11202002731YA (en) | 2017-10-17 | 2018-10-16 | Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one |
Country Status (21)
Country | Link |
---|---|
US (1) | US11236110B2 (ja) |
EP (1) | EP3697795B1 (ja) |
JP (1) | JP2020537648A (ja) |
KR (1) | KR20200071107A (ja) |
CN (1) | CN111263764A (ja) |
AR (1) | AR113770A1 (ja) |
AU (1) | AU2018353107B2 (ja) |
BR (1) | BR112020007359A2 (ja) |
CA (1) | CA3076765A1 (ja) |
CO (1) | CO2020005710A2 (ja) |
DK (1) | DK3697795T3 (ja) |
FI (1) | FI3697795T3 (ja) |
IL (1) | IL273751B2 (ja) |
LT (1) | LT3697795T (ja) |
MA (1) | MA50395A (ja) |
MX (1) | MX2020004214A (ja) |
PH (1) | PH12020550104A1 (ja) |
PT (1) | PT3697795T (ja) |
RU (1) | RU2020115274A (ja) |
SG (1) | SG11202002731YA (ja) |
WO (1) | WO2019076475A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021018824A1 (en) * | 2019-07-31 | 2021-02-04 | Esteve Pharmaceuticals, S.A. | Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
WO2008105497A1 (ja) | 2007-03-01 | 2008-09-04 | Mitsubishi Tanabe Pharma Corporation | ベンゾイミダゾール化合物およびその医薬用途 |
EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
WO2009032667A1 (en) | 2007-08-29 | 2009-03-12 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
PL2242759T3 (pl) | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
MA38569A1 (fr) * | 2013-04-23 | 2017-03-31 | Esteve Labor Dr | Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments |
EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
JP2017100951A (ja) * | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキサゾリジノン及びオキサジナノン誘導体 |
TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物 |
TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物 |
TWI685497B (zh) | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物 |
-
2018
- 2018-10-16 RU RU2020115274A patent/RU2020115274A/ru unknown
- 2018-10-16 LT LTEPPCT/EP2018/000470T patent/LT3697795T/lt unknown
- 2018-10-16 DK DK18796360.8T patent/DK3697795T3/da active
- 2018-10-16 AU AU2018353107A patent/AU2018353107B2/en active Active
- 2018-10-16 IL IL273751A patent/IL273751B2/en unknown
- 2018-10-16 PT PT187963608T patent/PT3697795T/pt unknown
- 2018-10-16 BR BR112020007359-8A patent/BR112020007359A2/pt unknown
- 2018-10-16 KR KR1020207013907A patent/KR20200071107A/ko not_active Application Discontinuation
- 2018-10-16 CN CN201880069276.1A patent/CN111263764A/zh active Pending
- 2018-10-16 SG SG11202002731YA patent/SG11202002731YA/en unknown
- 2018-10-16 MA MA050395A patent/MA50395A/fr unknown
- 2018-10-16 US US16/649,824 patent/US11236110B2/en active Active
- 2018-10-16 WO PCT/EP2018/000470 patent/WO2019076475A1/en unknown
- 2018-10-16 JP JP2020520801A patent/JP2020537648A/ja active Pending
- 2018-10-16 AR ARP180102999A patent/AR113770A1/es unknown
- 2018-10-16 CA CA3076765A patent/CA3076765A1/en active Pending
- 2018-10-16 EP EP18796360.8A patent/EP3697795B1/en active Active
- 2018-10-16 MX MX2020004214A patent/MX2020004214A/es unknown
- 2018-10-16 FI FIEP18796360.8T patent/FI3697795T3/fi active
-
2020
- 2020-03-20 PH PH12020550104A patent/PH12020550104A1/en unknown
- 2020-05-09 CO CONC2020/0005710A patent/CO2020005710A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
LT3697795T (lt) | 2024-04-10 |
PT3697795T (pt) | 2024-02-29 |
DK3697795T3 (da) | 2024-02-26 |
AR113770A1 (es) | 2020-06-10 |
RU2020115274A (ru) | 2021-11-01 |
EP3697795B1 (en) | 2023-11-22 |
WO2019076475A1 (en) | 2019-04-25 |
RU2020115274A3 (ja) | 2022-04-29 |
CA3076765A1 (en) | 2019-04-25 |
MX2020004214A (es) | 2020-08-13 |
JP2020537648A (ja) | 2020-12-24 |
IL273751A (en) | 2020-05-31 |
US11236110B2 (en) | 2022-02-01 |
EP3697795A1 (en) | 2020-08-26 |
BR112020007359A2 (pt) | 2020-09-29 |
PH12020550104A1 (en) | 2021-01-25 |
FI3697795T3 (fi) | 2024-02-23 |
US20200331929A1 (en) | 2020-10-22 |
MA50395A (fr) | 2020-08-26 |
CO2020005710A2 (es) | 2020-05-29 |
IL273751B1 (en) | 2023-10-01 |
CN111263764A (zh) | 2020-06-09 |
AU2018353107A1 (en) | 2020-04-23 |
TW201922752A (zh) | 2019-06-16 |
KR20200071107A (ko) | 2020-06-18 |
IL273751B2 (en) | 2024-02-01 |
AU2018353107B2 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276802A (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones | |
EP3661918A4 (en) | ANALOGUES OF 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE | |
AU2018258581A8 (en) | RAF-degrading conjugate compounds | |
IL282178A (en) | Products, uses and methods | |
EP3452481A4 (en) | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS | |
EP4219526A3 (en) | Method for preparing amg 416 | |
IL260488B (en) | History of 8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane | |
EP3660019C0 (en) | 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES | |
EP3846791A4 (en) | ILLUDIN ANALOGUES, THEIR USES AND PROCEDURES FOR THEIR SYNTHESIS | |
EP3421444A4 (en) | PROCESS FOR PRODUCING 1-CHLORO-2,3,3,3-TETRAFLUOROPROPENE | |
GB2577981B (en) | Methods, products & Uses relating thereto | |
IL285204A (en) | Formulation of apavicin, method for its preparation | |
GB201813648D0 (en) | Methods, products & uses relating thereto | |
IL273751A (en) | Salts of (r)-9-(5,2-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-9,4-diazaspiro[5.5]undecan-3-one | |
EP3222703B8 (en) | Tealight cups, tealights and methods for the production thereof | |
WO2016145111A3 (en) | Methods, systems and kits for enhanced muscle contractile capabilities | |
GB201817509D0 (en) | Products, uses & methods | |
EP3876894A4 (en) | ATTACHED | |
GB201912016D0 (en) | Methods, products & uses relating thereto | |
GB201815628D0 (en) | Belisha beacon | |
GB201709607D0 (en) | The P.I.R. Co. Ltd - business method patent | |
AU2018901799A0 (en) | New synthetic methods | |
EP3621618A4 (en) | TREATMENT OF GASTROPARESIA USING TRIAZASPIRO (4.5) DECANONE | |
GB201715900D0 (en) | Palate-transducers & palate-loudspeakers, new drawings | |
UA99984U (ru) | 8-(4-метилфенил)-6-оксо-3-(4-фторфенил)-3,4-дигидро-2h,6h-пиримидо[2,1-b][1,3,5]тиадиазин-7-карбонитрил |